ClinicalTrials.gg
CompletedNCT00987935Updated Mar 10, 2016Results posted

A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients

A Phase 2 interventional study of Sorafenib and BIBF 1120 in Carcinoma, Hepatocellular, sponsored by Boehringer Ingelheim. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-10.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 273 studies in Carcinoma, Hepatocellular with a site in Taiwan — 46 open to participants now, 69 under way, 11 of them phase 3. Carcinoma, Hepatocellular · Taiwan.

Enrollment
94th of 224
134 · median 98
Started
2009
with 18 others
Phase 2
70 of 273
14 open now
Registered
57th of 273
by date

Among the 273 studies in Carcinoma, Hepatocellular with a site in Taiwan, this one is the 94th largest by enrollment of the 224 interventional ones that give a count, is one of 19 that started in 2009, is one of 70 in phase 2, and was the 57th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

46 of the 273 studies in Carcinoma, Hepatocellular with a site in Taiwan are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 273 studies in Carcinoma, Hepatocellular with a site in Taiwan, or all of them as a file.
02

Study summary

This study is to evaluate the safety, appropriate dose, and efficacy of BIBF 1120 in liver cancer patients

03

Conditions studied

  • Carcinoma, Hepatocellular
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hepatocellular carcinoma, either histologically/ confirmed or clinically diagnosed, which is not amenable to curative surgery or loco-regional therapy
  2. Age 18 years or older
  3. Eastern Cooperative Group performance score of 2 or less
  4. score of 7 or less
  5. Written in accordance with International Conference on Harmonisation (ICH) and Good Clinical Practice (GCP) and local legislation

Exclusion criteria

Exclusion criteria:

  1. Prior systemic therapy for /unresectable hepatocellular carcinoma (for phase II)
  2. More than one line of prior systemic therapy for metastatic/unresectable hepatocellular carcinoma (for phase I)
  3. Uncontrolled or ascites to adequate medical therapy
  4. greater than 1.5 times
  5. Aspartate amino transferase or alanine amino transferase greater than 5 times upper limit of normal
  6. less than 1500/microliter
  7. count less than 75000/microliter
  8. less than 9 g/dL
  9. Serum creatinine greater than 1.5 times upper limit of normal
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    Nintedanib (BIBF 1120)

    Phase I dose escalation and phase II using dose determined in phase I

    Drug: BIBF 1120

  • Active comparator
    Sorafenib

    Twice daily dosing in phase II

    Drug: Sorafenib

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose in Phase I

    The MTD was defined as the highest dose studied for which the incidence of DLTs was 0/3 or less than 2/6 patients during the first treatment course.

    Time frame: 4 weeks

  2. Time to Progression (TTP) in Phase II

    TTP according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 criteria based on central independent review. TTP RECIST 1.0 was defined as the time from randomisation to disease progression according to RECIST 1.0.

    Time frame: From randomization until data cut-off (28 Sep 2012); Up to 77 weeks

Secondary outcomes

  1. Time to Progression (TTP) in Phase II (Follow-up Analyses)

    TTP according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 criteria based on central independent review. TTP RECIST 1.0 was defined as the time from randomisation to disease progression according to RECIST 1.0.

    Time frame: From randomization until disease progression or data cut-off (16 Jul 2014); Up to 171 weeks

  2. Incidence and Intensity of Adverse Events (AEs) Reported as the Number of Patients With AEs According to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Throughout the Treatment Period.

    Incidence and worst intensity (severity) of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0).

    Time frame: AEs with an onset during therapy with study treatment or within 28 days after discontinuation of study treatment (up to 1066 days)

  3. Incidence of Dose Limiting Toxicity in Phase I

    Number of patients with dose limiting toxicity are presented

    Time frame: 4 weeks

  4. Objective Tumour Response by RECIST

    Objective RECIST 1.0 tumour response was defined as Complete Response (CR) or Partial Response (PR) and was derived from the patient's best objective RECIST 1.0 response based on central independent review. 95% Confidence Interval presented below are computed by Clopper and Pearson method.

    Time frame: From randomization until data cut-off (16 July 2014); Up to 171 weeks

  5. Progression Free Survival (PFS)

    PFS by RECIST 1.0 was defined as the duration from date of randomisation to date of progression or death, whichever occurred earlier, based on central independent review.

    Time frame: From randomization until data cut-off (16 July 2014); Up to 171 weeks

  6. Overall Survival

    Overall survival was defined as the duration from date of randomisation to the date of death.

    Time frame: From randomization until data cut-off (16 July 2014); Up to 171 weeks

  7. AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of Nintedanib

    AUC0-12,ss,norm (area under the plasma concentration-time curve between 0 and 12 hours at steady state, normalised values) of Nintedanib Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.

    Time frame: Day1, Day15 and Day 16

  8. AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 (Metabolite of Nintedanib)

    AUC0-12,ss,norm (area under the plasma concentration-time curve between 0 and 12 hours at steady state, normalised values) of BIBF 1202 (metabolite of Nintedanib). Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.

    Time frame: Day1, Day15 and Day 16

  9. AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 Glucuronide (Metabolite of Nintedanib)

    AUC0-12,ss,norm of BIBF 1202 glucuronide (Metabolite of Nintedanib): Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.

    Time frame: Day1, Day15 and Day 16

  10. Cmax,ss,Norm (Maximum Concentration of the Nintedanib in Plasma at Steady State, Normalised Values)

    Cmax,ss,norm (maximum concentration of the Nintedanib in plasma at steady state, normalised values). Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.

    Time frame: Day1, Day15 and Day 16

  11. Cmax,ss,Norm (Maximum Concentration of the BIBF 1202 in Plasma at Steady State, Normalised Values)

    Cmax,ss,norm (maximum concentration of the BIBF 1202 in plasma at steady state, normalised values). Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.

    Time frame: Day1, Day15 and Day 16

  12. Cmax,ss,Norm (Maximum Concentration of the BIBF 1202 Glucuronide in Plasma at Steady State, Normalised Values)

    Cmax,ss,norm (maximum concentration of the BIBF 1202 glucuronide in plasma at steady state, normalised values). Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.

    Time frame: Day1, Day15 and Day 16

  13. fe0-12,ss (Fraction Excreted in Urine Between 0 and 12 Hours at Steady State) for Nintedanib

    fe0-12,ss (fraction excreted in urine between 0 and 12 hours at steady state) for Nintedanib. The reported value corresponds to the percentage of administered dose.

    Time frame: 0 to 4 hours (h), 4 to 12 h, and 12 to 24 h after nintedanib

07

Results

Posted Aug 27, 2015

Participant flow

The trial consisted of 2 Phases. Patients were stratified into 1 of 2 groups according to their aspartate aminotransferase (AST)/alanine aminotransferase (ALT) and Child-Pugh score at baseline.

Participant flow — Overall Study
MilestonePhase I Group I, 100 mg Nintedanib BidPhase I Group 1, 150 mg Nintedanib BidPhase I Group 1, 200 mg Nintedanib BidPhase I Group 2, 50 mg Nintedanib BidPhase I Group 2, 100 mg Nintedanib BidPhase I Group 2, 150 mg Nintedanib BidPhase I Group 2, 200 mg Nintedanib BidPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib Bid
Started433373166332
Completed000000110
Not completed433373156232
Withdrew: Progressive disease32325394823
Withdrew: Adverse event0101102106
Withdrew: Refused to continue taking trial med.100010442
Withdrew: Reason other than those specified above000000001

Outcome measures

PrimaryMaximum Tolerated Dose in Phase I

The MTD was defined as the highest dose studied for which the incidence of DLTs was 0/3 or less than 2/6 patients during the first treatment course.

Time frame:
4 weeks
Reported as:
Number · mg
Maximum Tolerated Dose in Phase I
mgGroup 1Group 2
Maximum Tolerated Dose in Phase I200200
PrimaryTime to Progression (TTP) in Phase II

TTP according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 criteria based on central independent review. TTP RECIST 1.0 was defined as the time from randomisation to disease progression according to RECIST 1.0.

Time frame:
From randomization until data cut-off (28 Sep 2012); Up to 77 weeks
Reported as:
Median · months
Time to Progression (TTP) in Phase II
monthsPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib Bid
Time to Progression (TTP) in Phase II2.73 (0.99 to 5.55)3.71 (1.77 to 7.36)
Statistical analysis
  • Phase II, 200 mg Nintedanib Bid vs Phase II, 400 mg Sorafenib Bid · Hazard ratio (hr): 1.357 · 95% CI 0.802 to 2.296Hazard ratio from Cox proportional hazards model stratified by macroscopic vacular invasion, extrahepatic spread, or both present vs both absent. HR below 1 favors Nintedanib.
SecondaryTime to Progression (TTP) in Phase II (Follow-up Analyses)

TTP according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 criteria based on central independent review. TTP RECIST 1.0 was defined as the time from randomisation to disease progression according to RECIST 1.0.

Time frame:
From randomization until disease progression or data cut-off (16 Jul 2014); Up to 171 weeks
Reported as:
Median · months
Time to Progression (TTP) in Phase II (Follow-up Analyses)
monthsPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib Bid
Time to Progression (TTP) in Phase II (Follow-up Analyses)2.76 (0.99 to 5.55)3.71 (1.77 to 7.36)
Statistical analysis
  • Phase II, 200 mg Nintedanib Bid vs Phase II, 400 mg Sorafenib Bid · Hazard ratio (hr): 1.213 · 95% CI 0.730 to 2.014Hazard ratio from Cox proportional hazards model stratified by macroscopic vacular invasion, extrahepatic spread, or both present vs both absent. HR below 1 favors Nintedanib.
SecondaryIncidence and Intensity of Adverse Events (AEs) Reported as the Number of Patients With AEs According to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Throughout the Treatment Period.

Incidence and worst intensity (severity) of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0).

Time frame:
AEs with an onset during therapy with study treatment or within 28 days after discontinuation of study treatment (up to 1066 days)
Reported as:
Number · participants
Incidence and Intensity of Adverse Events (AEs) Reported as the Number of Patients With AEs According to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Throughout the Treatment Period.
participantsPhase I Group I, 100 mg Nintedanib BidPhase I Group 1, 150 mg Nintedanib BidPhase I Group 1, 200 mg Nintedanib BidPhase I Group 2, 50 mg Nintedanib BidPhase I Group 2, 100 mg Nintedanib BidPhase I Group 2, 150 mg Nintedanib BidPhase I Group 2, 200 mg Nintedanib BidPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib Bid
Grade 10010101121
Grade 22210014154
Grade 321113251718
Grade 4000210185
Grade 50000205104
SecondaryIncidence of Dose Limiting Toxicity in Phase I

Number of patients with dose limiting toxicity are presented

Time frame:
4 weeks
Reported as:
Number · participants
Incidence of Dose Limiting Toxicity in Phase I
participantsPhase I Group 1, 100 mg Nintedanib BidPhase I Group 1, 150 mg Nintedanib BidPhase I Group 1, 200 mg Nintedanib BidPhase I Group 2, 50 mg Nintedanib BidPhase I Group 2, 100 mg Nintedanib BidPhase I Group 2, 150 mg Nintedanib BidPhase I Group 2, 200 mg Nintedanib Bid
Incidence of Dose Limiting Toxicity in Phase I0000100
SecondaryObjective Tumour Response by RECIST

Objective RECIST 1.0 tumour response was defined as Complete Response (CR) or Partial Response (PR) and was derived from the patient's best objective RECIST 1.0 response based on central independent review. 95% Confidence Interval presented below are computed by Clopper and Pearson method.

Time frame:
From randomization until data cut-off (16 July 2014); Up to 171 weeks
Reported as:
Number · percentage of participants
Objective Tumour Response by RECIST
percentage of participantsPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib Bid
Objective Tumour Response by RECIST6.3 (1.8 to 15.5)3.1 (0.1 to 16.2)
SecondaryProgression Free Survival (PFS)

PFS by RECIST 1.0 was defined as the duration from date of randomisation to date of progression or death, whichever occurred earlier, based on central independent review.

Time frame:
From randomization until data cut-off (16 July 2014); Up to 171 weeks
Reported as:
Median · months
Progression Free Survival (PFS)
monthsPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib Bid
Progression Free Survival (PFS)2.66 (0.99 to 5.55)3.71 (1.77 to 7.36)
Statistical analysis
  • Phase II, 200 mg Nintedanib Bid vs Phase II, 400 mg Sorafenib Bid · Hazard ratio (hr): 1.186 · 95% CI 0.728 to 1.932Hazard ratio from Cox proportional hazards model stratified by macroscopic vacular invasion, extrahepatic spread, or both present vs both absent. HR below 1 favors Nintedanib.
SecondaryOverall Survival

Overall survival was defined as the duration from date of randomisation to the date of death.

Time frame:
From randomization until data cut-off (16 July 2014); Up to 171 weeks
Reported as:
Median · months
Overall Survival
monthsPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib Bid
Overall Survival10.18 (5.19 to 16.85)10.71 (7.29 to 16.66)
Statistical analysis
  • Phase II, 200 mg Nintedanib Bid vs Phase II, 400 mg Sorafenib Bid · Hazard ratio (hr): 0.940 · 95% CI 0.593 to 1.489Hazard ratio from Cox proportional hazards model stratified by macroscopic vacular invasion, extrahepatic spread, or both present vs both absent. HR below 1 favors Nintedanib.
SecondaryAUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of Nintedanib

AUC0-12,ss,norm (area under the plasma concentration-time curve between 0 and 12 hours at steady state, normalised values) of Nintedanib Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.

Time frame:
Day1, Day15 and Day 16
Reported as:
Geometric mean · (ng*h/mL)/mg
AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of Nintedanib
(ng*h/mL)/mgGroup 1Group 2
AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of Nintedanib1.97 ± 97.13.82 ± 64.1
SecondaryAUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 (Metabolite of Nintedanib)

AUC0-12,ss,norm (area under the plasma concentration-time curve between 0 and 12 hours at steady state, normalised values) of BIBF 1202 (metabolite of Nintedanib). Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.

Time frame:
Day1, Day15 and Day 16
Reported as:
Geometric mean · (ng*h/mL)/mg
AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 (Metabolite of Nintedanib)
(ng*h/mL)/mgGroup 1Group 2
AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 (Metabolite of Nintedanib)3.50 ± 1578.95 ± 114
SecondaryAUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 Glucuronide (Metabolite of Nintedanib)

AUC0-12,ss,norm of BIBF 1202 glucuronide (Metabolite of Nintedanib): Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.

Time frame:
Day1, Day15 and Day 16
Reported as:
Geometric mean · (ng*h/mL)/mg
AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 Glucuronide (Metabolite of Nintedanib)
(ng*h/mL)/mgGroup 1Group 2
AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 Glucuronide (Metabolite of Nintedanib)16.9 ± 14445.0 ± 124
SecondaryCmax,ss,Norm (Maximum Concentration of the Nintedanib in Plasma at Steady State, Normalised Values)

Cmax,ss,norm (maximum concentration of the Nintedanib in plasma at steady state, normalised values). Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.

Time frame:
Day1, Day15 and Day 16
Reported as:
Geometric mean · (ng/mL)/mg
Cmax,ss,Norm (Maximum Concentration of the Nintedanib in Plasma at Steady State, Normalised Values)
(ng/mL)/mgGroup 1Group 2
Cmax,ss,Norm (Maximum Concentration of the Nintedanib in Plasma at Steady State, Normalised Values)0.348 ± 98.80.630 ± 68.9
SecondaryCmax,ss,Norm (Maximum Concentration of the BIBF 1202 in Plasma at Steady State, Normalised Values)

Cmax,ss,norm (maximum concentration of the BIBF 1202 in plasma at steady state, normalised values). Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.

Time frame:
Day1, Day15 and Day 16
Reported as:
Geometric mean · (ng/mL)/mg
Cmax,ss,Norm (Maximum Concentration of the BIBF 1202 in Plasma at Steady State, Normalised Values)
(ng/mL)/mgGroup 1Group 2
Cmax,ss,Norm (Maximum Concentration of the BIBF 1202 in Plasma at Steady State, Normalised Values)0.519 ± 1481.01 ± 118
SecondaryCmax,ss,Norm (Maximum Concentration of the BIBF 1202 Glucuronide in Plasma at Steady State, Normalised Values)

Cmax,ss,norm (maximum concentration of the BIBF 1202 glucuronide in plasma at steady state, normalised values). Detailed time points of sampling are: Phase I and selected phase II patients in the Nintedanib arm: Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15.

Time frame:
Day1, Day15 and Day 16
Reported as:
Geometric mean · (ng/mL)/mg
Cmax,ss,Norm (Maximum Concentration of the BIBF 1202 Glucuronide in Plasma at Steady State, Normalised Values)
(ng/mL)/mgGroup 1Group 2
Cmax,ss,Norm (Maximum Concentration of the BIBF 1202 Glucuronide in Plasma at Steady State, Normalised Values)1.56 ± 1393.48 ± 139
Secondaryfe0-12,ss (Fraction Excreted in Urine Between 0 and 12 Hours at Steady State) for Nintedanib

fe0-12,ss (fraction excreted in urine between 0 and 12 hours at steady state) for Nintedanib. The reported value corresponds to the percentage of administered dose.

Time frame:
0 to 4 hours (h), 4 to 12 h, and 12 to 24 h after nintedanib
Reported as:
Geometric mean · percentage
fe0-12,ss (Fraction Excreted in Urine Between 0 and 12 Hours at Steady State) for Nintedanib
percentageGroup 1Group 2
fe0-12,ss (Fraction Excreted in Urine Between 0 and 12 Hours at Steady State) for Nintedanib0.227 ± 94.60.286 ± 46.0

Adverse events

Collected over AEs with an onset during therapy with study treatment or within 28 days after discontinuation of study treatment (up to 1066 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I Group I Nintedanib, 100 mg Bid—2/4 (50%)4/4 (100%)
Phase I Group I Nintedanib, 150 mg Bid—1/3 (33.3%)3/3 (100%)
Phase I Group I Nintedanib, 200 mg Bid—0/3 (0%)3/3 (100%)
Phase I Group II Nintedanib, 50 mg Bid—3/3 (100%)3/3 (100%)
Phase I Group II Nintedanib, 100 mg Bid—4/7 (57.1%)7/7 (100%)
Phase I Group II Nintedanib, 150 mg Bid—1/3 (33.3%)3/3 (100%)
Phase I Group II Nintedanib, 200 mg Bid—10/16 (62.5%)16/16 (100%)
Phase II Nintedanib, 200 mg Bid—29/63 (46%)61/63 (96.8%)
Phase II Sorafenib, 400 mg Bid—18/32 (56.3%)32/32 (100%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventPhase I Group I Nintedanib, 100 mg BidPhase I Group I Nintedanib, 150 mg BidPhase I Group I Nintedanib, 200 mg BidPhase I Group II Nintedanib, 50 mg BidPhase I Group II Nintedanib, 100 mg BidPhase I Group II Nintedanib, 150 mg BidPhase I Group II Nintedanib, 200 mg BidPhase II Nintedanib, 200 mg BidPhase II Sorafenib, 400 mg Bid
Haemorrhagic anaemiaBlood and lymphatic system disorders0/40/30/31/30/70/30/160/630/32
Abdominal distensionGastrointestinal disorders0/41/30/30/31/70/30/160/631/32
Abdominal painGastrointestinal disorders0/40/30/31/30/70/31/161/631/32
Gastrointestinal haemorrhageGastrointestinal disorders0/40/30/31/30/70/30/161/630/32
Upper gastrointestinal haemorrhageGastrointestinal disorders0/40/30/31/30/71/30/163/631/32
HepatitisHepatobiliary disorders0/40/30/31/30/70/30/160/630/32
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/40/30/31/30/70/30/160/630/32
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/40/30/31/32/70/31/160/630/32
VomitingGastrointestinal disorders1/40/30/30/31/70/31/160/630/32
HeadacheNervous system disorders1/40/30/30/30/70/30/160/630/32
Most frequent other events
Showing 10 of 134
Most frequent other events
EventPhase I Group I Nintedanib, 100 mg BidPhase I Group I Nintedanib, 150 mg BidPhase I Group I Nintedanib, 200 mg BidPhase I Group II Nintedanib, 50 mg BidPhase I Group II Nintedanib, 100 mg BidPhase I Group II Nintedanib, 150 mg BidPhase I Group II Nintedanib, 200 mg BidPhase II Nintedanib, 200 mg BidPhase II Sorafenib, 400 mg Bid
DiarrhoeaGastrointestinal disorders2/41/30/32/35/73/36/1628/6318/32
Decreased appetiteMetabolism and nutrition disorders1/41/30/33/32/71/38/1625/638/32
HyponatraemiaMetabolism and nutrition disorders0/40/30/33/31/70/30/162/632/32
InsomniaPsychiatric disorders0/40/30/31/32/73/30/169/634/32
AnaemiaBlood and lymphatic system disorders1/40/31/32/31/71/33/1612/635/32
NeutropeniaBlood and lymphatic system disorders0/40/30/30/30/72/31/164/631/32
Abdominal distensionGastrointestinal disorders1/41/32/32/33/70/33/1618/633/32
Abdominal painGastrointestinal disorders0/42/32/32/31/71/32/1611/6310/32
NauseaGastrointestinal disorders2/41/31/32/32/72/37/1619/634/32
Mucosal inflammationGeneral disorders0/42/30/30/30/70/32/162/632/32

Baseline characteristics

Treated set (TS): Treated set included all patients who received at least one dose of trial medication

Age, Continuous
Age, Continuous(years)Phase I Group I, 100 mg Nintedanib BidPhase I Group 1, 150 mg Nintedanib BidPhase I Group 1, 200 mg Nintedanib BidPhase I Group 2, 50 mg Nintedanib BidPhase I Group 2, 100 mg Nintedanib BidPhase I Group 2, 150 mg Nintedanib BidPhase I Group 2, 200 mg Nintedanib BidPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib BidTotal
Mean44.5 ± 14.555.7 ± 4.247.7 ± 6.864.3 ± 15.362.3 ± 11.168.7 ± 10.156.1 ± 11.758.2 ± 12.661.2 ± 11.558.6 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Phase I Group I, 100 mg Nintedanib BidPhase I Group 1, 150 mg Nintedanib BidPhase I Group 1, 200 mg Nintedanib BidPhase I Group 2, 50 mg Nintedanib BidPhase I Group 2, 100 mg Nintedanib BidPhase I Group 2, 150 mg Nintedanib BidPhase I Group 2, 200 mg Nintedanib BidPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib BidTotal
Female00000136616
Male433372135726118
08

Study locations

16 sites
  • 1199.39.82001 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1199.39.82002 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1199.39.82003 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1199.39.82004 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1199.39.82005 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1199.39.82006 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1199.39.88606 Boehringer Ingelheim Investigational Site
    Changhua, Taiwan
  • 1199.39.88609 Boehringer Ingelheim Investigational Site
    Kaohsiung, Taiwan
  • 1199.39.88610 Boehringer Ingelheim Investigational Site
    Kaohsiung, Taiwan
  • 1199.39.88605 Boehringer Ingelheim Investigational Site
    Taichung, Taiwan
  • 1199.39.88608 Boehringer Ingelheim Investigational Site
    Tainan City, Taiwan
  • 1199.39.88602 Boehringer Ingelheim Investigational Site
    Tainan, Taiwan
  • 1199.39.88601 Boehringer Ingelheim Investigational Site
    Taipei, Taiwan
  • 1199.39.88603 Boehringer Ingelheim Investigational Site
    Taipei, Taiwan
  • 1199.39.88604 Boehringer Ingelheim Investigational Site
    Taoyuan County, Taiwan
  • 1199.39.88607 Boehringer Ingelheim Investigational Site
    Yunlin County, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Jul 2014 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2009
First posted
Oct 1, 2009
Start
Oct 2009
Primary completionActual
Jul 2014
CompletionActual
Jan 2016
Results first posted
Aug 27, 2015
Last update
Mar 10, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00987935
Responsible party
Sponsor
First posted
Oct 1, 2009
Start date
Oct 2009
Primary completion
Jul 2014
Completion
Jan 2016
Results posted
Aug 27, 2015
Last update
Mar 10, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion